Global Antiplatelet Drugs Market, By Drug (Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Others), Indication (Myocardial Infraction, Percutaneous Coronary Interventions, Arterial Thrombosis, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Antiplatelet Drugs Market Analysis and Size
The surge in number of percutaneous coronary interventions is likely to drive demand for antiplatelet medications. Companies are intent on discovering novel molecular targets of common antiplatelet drugs, which is expected to pave the way for advanced antiplatelet therapies in the industry. Researchers focus on understanding the mechanisms of absorption of oral antiplatelet agents in patients, which is likely to help them improve effectiveness of current and emerging antiplatelet therapies. Furthermore, the rise in reagent rental business and emerging economies extend profitable opportunities to the market players in the forecast period.
Data Bridge Market Research analyses that the antiplatelet drugs market which was USD 2.18 billion in 2022, is likely to reach USD 4.01 billion by 2030, and is expected to undergo a CAGR of 8.15% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user segment of the antiplatelet drugs market owing to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antiplatelet Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Drug (Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Others), Indication (Myocardial Infraction, Percutaneous Coronary Interventions, Arterial Thrombosis, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Boehringer Ingelheim International GmbH. (Germany), Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc. (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Otsuka America Pharmaceutical, Inc. (U.S.), Lilly.(U.S.), AbbVie Inc. (U.S.), Genentech, Inc. (U.S.), Baxter (U.S.), Bausch Health Companies Inc. (Canada) among others
|
|
Market Opportunities
|
|
Market Definition
The antiplatelet drugs market is the segment of the pharmaceutical industry that involves the research, development, manufacturing, and distribution of medications designed to prevent the formation of blood clots by inhibiting platelet aggregation. Platelets are a type of blood cell responsible for clotting, which is an essential process to prevent excessive bleeding after an injury. However, in certain medical conditions, the formation of unwanted blood clots can lead to serious health issues, such as heart attacks, strokes, and deep vein thrombosis.
Antiplatelet drugs are used to reduce the risk of blood clot formation by interfering with various pathways and mechanisms involved in platelet aggregation. These drugs are commonly prescribed to individuals with a history of cardiovascular diseases, such as atherosclerosis, angina, and previous heart attacks or strokes. They are also used for patients undergoing certain medical procedures, such as coronary artery stent placement or coronary artery bypass surgery, to prevent clotting at the site of intervention.
Global Antiplatelet Drugs Market Dynamics
Drivers
- Increasing Prevalence of Chronic Blood Diseases
The cases of chronic blood diseases are growing exponentially and will likely drive the worldwide antiplatelet drugs market. Increase in the prevalence of chronic diseases such as cardiovascular diseases is owing to drive the market. The rising incidences of cardiovascular diseases is a major factor driving the antiplatelet drugs market's growth rate. In both developed and developing economies, cardiovascular illnesses are the leading cause of death.
According to the Centers for Disease Control and Prevention (CDC), over 8,00,000 individuals in the U.S. die each year from stroke and other cardiovascular disorders.
For instance, a study by the World Health Organization (WHO) has stated that cardiovascular diseases (CVDs) account for about 31% of all patient mortality each year.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of antiplatelet drugs market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness myriad fungal infections will expand the antiplatelet drugs market. Additionally, high disposable income and sedentary lifestyle of people will result in the expansion of the antiplatelet drugs market. Along with this, rising geriatric population and surge in thrombotic events will enhance the market's growth rate.
- Rising Number of Geriatric Population
Expanding geriatric population worldwide is predicted to favour antiplatelet drugs demand as this population is more prone to heart diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, which can foster the demand for antiplatelet drugs across the globe.
According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.
Opportunity
- Increase in the Number of Research and Development Activities
Rising clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period from 2023 to 2030.Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the antiplatelet drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
The rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the antiplatelet drugs market during the forecast period from2023 to 2030.
Restraint/Challenge
On the other hand, the high cost associated with the antiplatelet drugs are expected to obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and limitations in safety, efficacy and tolerability of some antiplatelet drugs will challenge the antiplatelet drugs market. Moreover, the availability of counterfeit drugs and side effects linked with antiplatelet drugs is expected to restrain and further impede the growth rate of market during the forecast period in the forecast period of 2023 to 2030.
This antiplatelet drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antiplatelet drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2021, Alfasigma announced the approval of the European license for bentracimab from PhaseBio. Bentracimab is a novel human monoclonal antibody fragment that has been shown to reverse the antiplatelet effects of Brilinta / Brilique in previous clinical tests
Global Antiplatelet Drugs Market Scope
The antiplatelet drugs market is segmented on the basis of drug, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Aspirin
- Clopidogrel
- Ticagrelor
- Prasugrel
- Others
Indication
- Myocardial Infraction
- Percutaneous Coronary Interventions
- Arterial Thrombosis
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Antiplatelet Drugs Market Regional Analysis/Insights
The antiplatelet drugs market is analysed and market size insights and trends are provided by country, drug, indication, route of administration, end-users and distribution channel as referenced above.
The countries covered in the antiplatelet drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the antiplatelet drugs market due to growing adoption of newer technologies and increasing demand for diseases-specific treatment. Additionally, the growing presence of major key players and rising healthcare expenditure will further propel the market's growth rate within region.
Europe is expected to grow during the forecast period of 2023 to 2030 due to the surging number of myocardial infraction cases and rising government initiatives in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The antiplatelet drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for antiplatelet drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the antiplatelet drugs market. The data is available for historic period from 2010 to 2021.
Competitive Landscape and Antiplatelet Drugs Market Share Analysis
The antiplatelet drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to antiplatelet drugs market.
Some of the major players operating in the antiplatelet drugs market are
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Bayer AG (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Merck & Co., Inc. (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Otsuka America Pharmaceutical, Inc. (U.S.)
- Lilly. (U.S.)
- AbbVie Inc. (U.S.)
- Genentech, Inc. (U.S.)
- Baxter (U.S.)
- Bausch Health Companies Inc. (Canada)
SKU-